he heart rate (HR) responses to sugammadex to reverse moderate to deep NMB during a steady-state period and sought mechanisms for HR changes. METHODS: Patients with normal sinus rhythm, who were undergoing elective surgery that included rocuronium for NMB, were evaluated. After surgery, while at steady-state surgical depth anesthesia with sevoflurane and mechanical ventilation, patients received either placebo or 2 or 4 mg/kg of sugammadex to reverse moderate to deep NMB. Study personnel involved in data analysis were blinded to treatment. Continuous electrocardiogram (ECG) was recorded from the 5 minutes before and 5 minutes after sugammadex/placebo administration. R-R intervals were converted to HR and averaged in 1-minute increments. The maximum prolongation of an R-R interval after sugammadex was converted to an instantaneous HR. RESULTS: A total of 63 patients were evaluated: 8 received placebo, and 38 and 17 received 2 and 4 mg/kg sugammadex. Age, body mass index, and patient factors were similar in groups. Placebo did not elicit HR changes, whereas sugammadex caused maximum instantaneous HR slowing (calculated from the longest R-R interval), ranging from 2 to 19 beats/min. There were 7 patients with maximum HR slowing >10 beats/min. The average HR change and 95% confidence interval (CI) during the 5 minutes after 2 mg/kg sugammadex were 3.1 (CI, 2.3–4.1) beats/min, and this was not different from the 4 mg/kg sugammadex group (4.1 beats/min [CI, 2.5–5.6]). HR variability derived from the standard deviation of consecutive R-R intervals increased after sugammadex. CONCLUSIONS: Sugammadex to reverse moderate and deep NMB resulted in a fast onset and variable magnitude of HR slowing in patients. A difference in HR slowing as a function of dose did not achieve statistical significance. The observational nature of the investigation prevented a full understanding of the mechanism(s) of the HR slowing....

中文翻译：

---

表征从服用舒更葡糖到逆转神经肌肉阻滞对心率的影响：一项在患者中的观察性研究

他对舒更葡糖的心率 (HR) 反应在稳态期间逆转中度至深度 NMB，并寻找 HR 变化的机制。方法：对接受包括罗库溴铵治疗 NMB 的择期手术的正常窦性心律的患者进行评估。手术后，在使用七氟醚和机械通气进行稳态手术深度麻醉时，患者接受安慰剂或 2 或 4 mg/kg 舒更葡糖以逆转中度至深度 NMB。参与数据分析的研究人员对治疗不知情。从 sugammadex/安慰剂给药前 5 分钟和给药后 5 分钟记录连续心电图 (ECG)。RR 间期转换为 HR 并以 1 分钟为增量进行平均。将舒更葡糖后 RR 间期的最大延长转换为瞬时 HR。结果：共评估了 63 名患者：8 名接受安慰剂，38 名和 17 名接受 2 和 4 mg/kg 舒更葡糖。年龄、体重指数和患者因素在各组中相似。安慰剂没有引起心率变化，而舒更葡糖导致最大瞬时心率减慢（从最长的 RR 间期计算），范围从 2 到 19 次/分钟。有 7 名患者最大 HR 减慢>10 次/分钟。2 mg/kg sugammadex 后 5 分钟内的平均 HR 变化和 95% 置信区间 (CI) 为 3.1 (CI, 2.3–4.1) 次/分钟，这与 4 mg/kg sugammadex 组没有区别 (4.1心跳/分钟 [CI, 2.5–5.6])。舒更葡糖后，源自连续 RR 间期标准差的 HR 变异性增加。结论：舒更葡糖逆转中度和深度 NMB 导致患者 HR 减慢的快速发作和可变幅度。作为剂量函数的 HR 减慢的差异没有达到统计学意义。调查的观察性质阻碍了对 HR 减慢机制的全面理解……